Mazdutide (IBI362): Uses, Dosing Approach, Preparation Basics, Effects, and Side Effects

What Is Mazdutide?

Mazdutide, also known as IBI362, is a dual-acting medication designed to stimulate both GLP-1 (glucagon-like peptide-1) and glucagon receptors. While traditional GLP-1 therapies mainly focus on reducing appetite, mazdutide adds a second pathway by increasing energy expenditure through glucagon receptor activation.

This combined action targets both sides of weight regulation: calorie intake and calorie burn. Sixpex IBI362

Key features:

• Reduces appetite through GLP-1 receptor activation

• Increases energy expenditure via glucagon receptor stimulation

• May improve insulin sensitivity

• Supports greater fat oxidation

• Designed primarily for obesity and metabolic conditions

Because of its dual-receptor activity, mazdutide differs mechanistically from GLP-1–only medications.

---

Dosing Structure and Escalation Strategy

Mazdutide is typically administered once per week by subcutaneous injection. Like most incretin-based therapies, dosing is gradually increased to reduce gastrointestinal discomfort and improve tolerance.

Standard clinical dose levels

• 3 mg once weekly – initial adaptation dose

• 6 mg once weekly

• 9 mg once weekly – highest studied clinical level

Example titration schedule

• Weeks 1–4: 3 mg

• Weeks 5–8: 6 mg

• Week 9 onward: 9 mg

Not everyone needs to move up to 9 mg. Clinical data suggest many individuals achieve meaningful fat loss at 6 mg.

Reasons to pause dose escalation

• Ongoing nausea or vomiting

• Excessive weakness or fatigue

• Elevated heart rate or palpitations

• Satisfactory weight or fat reduction already achieved

With mazdutide, tolerability often determines the optimal dose rather than simply increasing to the maximum level.

---

Solution Preparation Overview (Conceptual)

Mazdutide is given as a subcutaneous injection. Depending on the formulation, it may come as a prefilled device or as a powder that requires reconstitution.

Basic concentration principle

• A set milligram amount is dissolved into a defined milliliter volume

• This creates a measurable concentration

• Concentration formula: mg ÷ ml

Conceptual example:

• 9 mg combined with 1.5 ml diluent

• Final concentration: 6 mg per ml

• 0.5 ml = 3 mg

• 1.0 ml = 6 mg

Accurate dilution is critical for correct dosing. This explanation is for general understanding only.

---

Timeline of Effects

Early phase (3 mg)

• Noticeable appetite reduction

• Feeling full sooner

• Mild rise in resting energy expenditure

Mid phase (6 mg, Weeks 5–8)

• Clearer fat and weight reduction

• Reduction in visceral fat

• Improved metabolic flexibility

Later phase (9 mg)

• Stronger fat oxidation

• Higher overall energy output

• Sustained appetite suppression

---

Reported Weight Loss Outcomes

Clinical observations suggest dose-related reductions in body weight:

• 3 mg: roughly 6–8% reduction

• 6 mg: around 10–15% reduction

• 9 mg: 15–20% or more in longer studies

Fat mass tends to decrease more than lean mass, likely due to the added glucagon-related increase in energy expenditure.

---

Potential Side Effects

Side effects generally increase with dose.

Most common

• Nausea

• Reduced appetite

• Stomach discomfort

• Mild diarrhea or constipation

More likely at higher doses

• Vomiting

• Increased heart rate

• Fatigue

• Heat sensitivity or increased sweating

---

Ways to Improve Tolerability

• Increase the dose gradually

• Avoid very large or high-fat meals

• Stay well hydrated

• Monitor heart rate during early weeks

• Adjust dose if fatigue becomes excessive

---

Higher-Risk Individuals

• Those with a history of heart rhythm disorders

• Individuals with uncontrolled high blood pressure

• History of pancreatitis

• Pregnant or breastfeeding individuals

Because mazdutide stimulates the glucagon receptor in addition to GLP-1, careful monitoring is especially important in people with cardiovascular or metabolic conditions.

---

Summary

Mazdutide (IBI362) is a dual-action metabolic therapy that combines GLP-1–driven appetite suppression with glucagon-mediated energy expenditure. Studied doses range from 3 mg to 9 mg weekly, with gradual titration used to improve tolerability.

• Targets both calorie intake and calorie burn

• Dose escalation improves tolerance

• Strong potential for meaningful fat reduction

When used carefully and monitored appropriately, mazdutide represents a promising approach for obesity and advanced metabolic management.